Progress in the application of dupilumab in pediatric dermatoses
10.3760/cma.j.cn112150-20250128-00080
- VernacularTitle:度普利尤单抗在儿童皮肤疾病中的应用进展
- Author:
Siyan YANG
1
;
Jing SUN
;
Shan WANG
;
Bin ZHANG
Author Information
1. 郑州大学附属儿童医院 河南省儿童医院 郑州儿童医院皮肤科，郑州 450000
- Publication Type:Journal Article
- Keywords:
Dupilumab;
Pediatrics;
Type 2 inflammation;
Atopic dermatitis
- From:
Chinese Journal of Preventive Medicine
2025;59(9):1575-1583
- CountryChina
- Language:Chinese
-
Abstract:
Dupilumab is a fully human monoclonal antibody that exerts its effects by targeting and binding to the interleukin (IL)-4 receptor alpha subunit, thereby blocking IL-4/13 signaling and downregulating Type 2 inflammation. It has been approved in China for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 6 months and older, as well as prurigo nodularis (PN) and bullous pemphigoid in adults. Given its approval age and safety profile, the application of Dupilumab in children has unique advantages, and it has been widely used in the treatment of various Type 2 inflammation-associated and other pediatric dermatologic conditions.Early and proactive management of type 2 inflammatory dermatoses may have preventive and therapeutic implications for modulating the atopic march and type 2 inflammatory comorbidities. This article reviews and summarizes the recent applications of dupilumab in pediatric dermatological diseases.
